A Phase 1, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous NS101 Infusion in Healthy Volunteers
Latest Information Update: 26 Dec 2022
At a glance
- Drugs NS 101 Neuracle Science (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions; First in man
- Sponsors Neuracle Science
- 21 Dec 2022 Status changed from active, no longer recruiting to completed.
- 23 Aug 2022 Planned End Date changed from 3 Feb 2023 to 4 Jan 2023.
- 23 Aug 2022 Status changed from recruiting to active, no longer recruiting.